Cartesian Therapeutics' stock has rebounded sharply recently despite no significant news, driven partly by insider buying after a disappointing Phase 2b trial for Descartes-08 in myasthenia gravis. The company leverages its RNA Armory platform for mRNA cell therapies, focusing on autoimmune diseases, with Descartes-08 and Descartes-15 as its main assets. Descartes-08 showed mixed results in Phase 2b for MG, raising concerns due to endpoint changes and trial anomalies, yet plans continue for a pivotal trial in 2025.
Cartesian Therapeutics, Inc. (RNAC) came out with a quarterly loss of $0.69 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to loss of $2.40 per share a year ago.
Cartesian Therapeutics, Inc. (RNAC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
14 Aug 2025 (In 3 weeks) Date | | - Cons. EPS | - EPS |
6 May 2025 Date | | - Cons. EPS | - EPS |
5 Mar 2025 Date | | - Cons. EPS | - EPS |
11 Nov 2024 Date | | - Cons. EPS | - EPS |
15 Aug 2024 Date | | - Cons. EPS | 0.54 EPS |
14 Aug 2025 (In 3 weeks) Date | | - Cons. EPS | - EPS |
6 May 2025 Date | | - Cons. EPS | - EPS |
5 Mar 2025 Date | | - Cons. EPS | - EPS |
11 Nov 2024 Date | | - Cons. EPS | - EPS |
15 Aug 2024 Date | | - Cons. EPS | 0.54 EPS |
Biotechnology Industry | Healthcare Sector | Carsten Brunn CEO | NASDAQ (NMS) Exchange | 816212302 Cusip |
US Country | 66 Employees | - Last Dividend | 5 Apr 2024 Last Split | - IPO Date |
Cartesian Therapeutics, Inc. is a trailblazing clinical-stage biotechnology firm dedicated to advancing the field of medicine through its innovative approach in mRNA cell therapies. With a focus on treating various autoimmune diseases, the company stands at the forefront of developing therapies that aim to revolutionize the way such conditions are treated. Cartesian Therapeutics is founded on a commitment to leveraging advanced science to create impactful solutions for patients struggling with autoimmune disorders. Headquartered in Gaithersburg, Maryland, the company embodies a spirit of innovation and a relentless pursuit of excellence in biotechnology.
Cartesian Therapeutics, Inc. has developed a robust pipeline of groundbreaking mRNA cell therapies designed to address a wide range of autoimmune diseases through innovative treatment modalities. Here's an overview of their leading products under development: